Page last updated: 2024-09-05

sorafenib and carbostyril

sorafenib has been researched along with carbostyril in 20 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(carbostyril)
Trials
(carbostyril)
Recent Studies (post-2010) (carbostyril)
6,5207305,25112,8551,3235,611

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (20.00)29.6817
2010's15 (75.00)24.3611
2020's1 (5.00)2.80

Authors

AuthorsStudies
Chintala, L; El Naggar, AK; Gagel, R; Hong, D; Kurzrock, R; Wright, J; Ye, L1
Cohen, PR; Diwan, AH; Evans, HL; Hong, DS; Kurzrock, R; Prieto, VG; Reddy, SB; Tannir, NM; Wright, JJ1
Blaskovich, MA; El Naggar, AK; Gagel, RF; Hong, DS; Khan, R; Kurzrock, R; Moulder, S; Naing, A; Newman, RA; Ng, CS; Sebti, SM; Sherman, SI; Tannir, NM; Trent, J; Wheler, JJ; Wright, JJ; Ye, L1
Le Moulec, S; Loriot, Y; Soria, JC1
Bidyasar, S; Busaidy, NL; Cabanillas, ME; El Naggar, AK; Hernandez, M; Hong, DS; Kurzrock, R; Naing, A; Sherman, SI; Tsimberidou, AM; Waguespack, SG; Wheler, J; Wright, J; Ye, L1
Rexer, H1
Chen, KF; Chen, PJ; Cheng, AL; Ko, CH; Lin, MW; Liu, CY; Shiau, CW; Tai, WT1
Akerley, WL; Flaherty, LE; Kirkwood, JM; Lao, CD; Margolin, KA; Moon, J; Othus, M; Sondak, VK; Sosman, JA1
Shlomai, A1
Beuselinck, B; Blesius, A; Chevreau, C; Escudier, B; Oudard, S; Ravaud, A; Rolland, F1
Angevin, E; Castellano, D; Chang, J; Escudier, B; Gschwend, JE; Harzstark, A; Kay, A; Lin, CC; Lopez-Martin, JA; Sen, P; Shi, M; Soria, JC1
Atkins, J; Busaidy, N; Fu, S; Hong, D; Kurzrock, R; Naing, A; Sherman, S; Wheler, J1
Chen, K; Li, B; Shen, J; Wang, G; Wang, H; Xu, Z; Yang, M; Zeng, B; Zhu, W1
Schmidinger, M1
Bjarnason, GA; Cai, C; Davis, ID; De Giorgi, U; Escudier, B; Esteban, E; Grünwald, V; Kollmannsberger, C; Lee, JL; Marker, M; Melichar, B; Motzer, RJ; Porta, C; Rha, SY; Shi, MM; Squires, M; Sternberg, CN; Szczylik, C; Urbanowitz, G; Vogelzang, NJ; Zolnierek, J1
Balar, AV; Bangalore, S; Kang, SK; Ohmann, EL; Volodarskiy, A1
Balsara, B; Chan, SL; Chao, Y; Cheng, AL; Han, G; Ikeda, M; Kang, YK; Kudo, M; Lim, HY; Numata, K; Pan, H; Poon, RT; Rodriguez, AM; Sukeepaisarnjaroen, W; Thongprasert, S; Wang, Y; Wu, CC; Yang, TS; Zhang, Y1
Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A1
Abrey, LE; Aldape, K; Chang, S; Cloughesy, TF; Dancey, JE; DeAngelis, LM; Drappatz, J; Ebiana, VA; Gilbert, M; Kuhn, J; Levin, VA; Lieberman, F; Mehta, MP; Nghiemphu, PL; Prados, M; Robins, HI; Wen, P; Wright, JJ; Yung, WKA1
Abou-Seri, SM; Arafa, RK; El-Fakharany, ZS; Nissan, YM; Sedky, NK1

Reviews

2 review(s) available for sorafenib and carbostyril

ArticleYear
Efficacy and Safety of Selective Vascular Endothelial Growth Factor Receptor Inhibitors Compared with Sorafenib for Metastatic Renal Cell Carcinoma: a Meta-analysis of Randomised Controlled Trials.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2016, Volume: 28, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzimidazoles; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Quinolines; Quinolones; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate; Vascular Endothelial Growth Factor A

2016
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
    European urology, 2017, Volume: 71, Issue:3

    Topics: Anilides; Antineoplastic Agents; Axitinib; Benzimidazoles; Bevacizumab; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Quinolines; Quinolones; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2017

Trials

10 trial(s) available for sorafenib and carbostyril

ArticleYear
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Nov-15, Volume: 15, Issue:22

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Farnesyltranstransferase; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ret; Pyridines; Quinolones; Sorafenib; Treatment Outcome

2009
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
    The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:4

    Topics: Adenocarcinoma, Follicular; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Neuroendocrine; Cell Differentiation; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; Female; Humans; Male; MAP Kinase Kinase Kinases; Middle Aged; Niacinamide; Oncogene Protein p21(ras); Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Quinolones; raf Kinases; Signal Transduction; Sorafenib; Thyroid Neoplasms

2011
[Third-line therapy for metastasized renal cell carcinoma: a randomized, multicenter non-blinded phase III study to compare safety and effectiveness of TF1258 versus sorafenib in patients with metastasized renal cell carcinoma following failure of antiang
    Der Urologe. Ausg. A, 2011, Volume: 50, Issue:10

    Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Carcinoma, Renal Cell; Disease Progression; Female; Germany; Humans; Kidney Neoplasms; Male; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Quinolones; Sorafenib; Survival Rate; TOR Serine-Threonine Kinases; Treatment Failure; Vascular Endothelial Growth Factor A

2011
Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Feb-15, Volume: 18, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Quinolones; Sirolimus; Sorafenib; Survival Analysis; Treatment Outcome

2012
Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.
    Clinical genitourinary cancer, 2013, Volume: 11, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinolones; Salvage Therapy; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Failure; Treatment Outcome

2013
Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Mar-01, Volume: 19, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Renal Cell; Drug Evaluation, Preclinical; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Quinolones; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor beta; Sorafenib; Survival Rate; Tissue Distribution; Vascular Endothelial Growth Factor Receptor-1

2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Disease Progression; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Quinolines; Quinolones; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome; Valproic Acid

2013
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolones; Sorafenib; Vascular Endothelial Growth Factor A

2014
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma.
    Hepatology (Baltimore, Md.), 2016, Volume: 64, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Asia, Eastern; Benzimidazoles; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Middle Aged; Niacinamide; Phenylurea Compounds; Quinolones; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays

2016
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.
    Journal of neuro-oncology, 2018, Volume: 136, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Quinolones; Sorafenib; Treatment Outcome

2018

Other Studies

8 other study(ies) available for sorafenib and carbostyril

ArticleYear
Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:5

    Topics: Adult; Amino Acid Sequence; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Medullary; Cell Line, Tumor; Exons; Humans; Male; Molecular Sequence Data; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyridines; Quinolones; Sorafenib; Thyroid Neoplasms

2008
Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
    Archives of dermatology, 2008, Volume: 144, Issue:6

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Diagnosis, Differential; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinolones; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib

2008
[Targeting KRAS pathway in NSCLC therapy].
    Bulletin du cancer, 2009, Volume: 96 Suppl

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Farnesyltranstransferase; Genes, ras; Humans; Lung Neoplasms; Mice; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Quinolones; raf Kinases; ras Proteins; Sorafenib

2009
Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:2

    Topics: Animals; Apoptosis; Benzenesulfonates; Benzimidazoles; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Molecular Structure; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyridines; Quinolones; RNA Interference; Sorafenib; STAT3 Transcription Factor; Tumor Burden; Xenograft Model Antitumor Assays

2012
Targeting late SV40 factor: is the achilles heel of hepatocarcinogenesis revealed?
    World journal of gastroenterology, 2012, Dec-14, Volume: 18, Issue:46

    Topics: Animals; Antineoplastic Agents; Benzodioxoles; Carcinoma, Hepatocellular; Cell Death; Clinical Trials as Topic; DNA-Binding Proteins; Humans; Liver Neoplasms; Niacinamide; Oncogenes; Phenotype; Phenylurea Compounds; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinolones; Sorafenib; Transcription Factors

2012
Overman rearrangement and Pomeranz-Fritsch reaction for the synthesis of benzoazepinoisoquinolones to discover novel antitumor agents.
    European journal of medicinal chemistry, 2013, Volume: 70

    Topics: Antineoplastic Agents; Benzazepines; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; HCT116 Cells; Hep G2 Cells; Humans; Indoles; K562 Cells; Melanoma; Molecular Structure; Niacinamide; Phenylurea Compounds; Quinolones; Sorafenib; Structure-Activity Relationship; Sulfonamides; Vemurafenib

2013
Third-line dovitinib in metastatic renal cell carcinoma.
    The Lancet. Oncology, 2014, Volume: 15, Issue:3

    Topics: Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolones; Sorafenib

2014
New proapoptotic chemotherapeutic agents based on the quinolone-3-carboxamide scaffold acting by VEGFR-2 inhibition.
    Scientific reports, 2023, 07-13, Volume: 13, Issue:1

    Topics: Antineoplastic Agents; bcl-2-Associated X Protein; Caspase 7; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Quinolones; Sorafenib; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2

2023